Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic

Mingyue Xu, Ruiying Chen, Yifeng Wang, Xiaoyun Huang, Hanzhen Zhang, Wenqian Zhao, Min Zhang, Yunyu Xu, Shaojun Liu, Chuan‐Ming Hao, Qionghong XieClinical 2024 · DOI

Abstract

Obinutuzumab was an effective treatment option for patients with membranous nephropathy. On the other hand, it was associated with a higher incidence of severe pneumonia following COVID-19 infection compared to other immunosuppressive regimens.
BibTeX
@inproceedings{xu2024obinutuzumab,
  author = {Mingyue Xu and Ruiying Chen and Yifeng Wang and Xiaoyun Huang and Hanzhen Zhang and Wenqian Zhao and Min Zhang and Yunyu Xu and Shaojun Liu and Chuan‐Ming Hao and Qionghong Xie},
  title = {{Obinutuzumab treatment for membranous nephropathy: effectiveness and safety concerns during the COVID-19 pandemic}},
  booktitle = {Clinical},
  year = {2024},
  doi = {10.1093/ckj/sfae299},
}

Loading related content...

Figure